Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Pharm ; 626: 122070, 2022 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-36041591

RESUMO

This study aims to characterize the rheological behavior of a novel phenylboronic acid (PBA)-based closomer nanoconjugate (Closogel) with potential application in pharmaceutical formulation. PBA was used as a cross-linking agent and model (antiviral) drug. The PBA loaded Closogel chemical structure was analyzed by boron (11B) NMR and Fourier transform infrared (FTIR) spectroscopy. The Closogel and control hydroxyethyl cellulose (HEC) gel were analyzed under oscillatory and continuous shear rheometry followed by mathematical modeling to characterize the gel flow behavior. The chemical analysis confirmed the existence of characteristic borate esters peaks and Boron chemical shifts within Closogel spectra. Due to its more flexible molecular structure, undiluted Closogel exhibited lower, yield stress, viscosity and relaxation time (30 Pa &163 Pa.s & 0.21 s vs 45 Pa &301 Pa.s & 0.39 s for HEC). Both Closogel and HEC gels exhibited a thixotropic behavior. The plastic undiluted and pseudoplastic 2.5 % w/v aqueous Closogels were more viscous than elastic (tan (δ) > 1) in the linear viscoelastic range. The Herschel-Bulkley model showed a significant fitting to all experimental data (R2 > 0.95). The 0.25 % w/v aqueous Closogel nearly exhibited a Newtonian behavior with a flow index of 0.93. These data suggest that PBA loaded Closomer-based gels have similar rheological behavior, with lower complex modulus than that of HEC gels, and they can be a promising platform used for delivery of topical antiviral or other bioactive agents.


Assuntos
Boratos , Nanoconjugados , Antivirais , Boro , Ácidos Borônicos , Celulose/química , Ésteres , Géis , Plásticos , Reologia/métodos , Viscosidade
2.
Assay Drug Dev Technol ; 19(8): 508-525, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34757813

RESUMO

It is hypothesized that L-arginine (ARG) can improve etoposide (VP-16) water solubility while preserving its anticancer activity. Factorial design is used to identify conditions for optimum drug aqueous solubility after freeze-drying. The physicochemical properties of the optimized formulation is further analyzed by X-ray powder diffraction, scanning electron microscopy, proton nuclear magnetic resonance, and fourier transform infrared spectroscopy. Drug stability in formulation is analyzed using mass spectrometry based fragmentation analysis. Liquid chromatography tandem mass spectrometry and cell viability assay on Michigan Cancer Foundation-7 (MCF-7) cell line are performed to assess the drug cellular uptake and the anticancer activity, respectively. At the VP-16: ARG ratio of 4:10 (w/w), the drug apparent solubility increased significantly (∼65-folds) with a 3.5-fold improvement in the drug dissolution rate. The interaction between VP-16 and ARG transforms the drug from crystalline to amorphous solid state. VP-16-ARG complex in lower native drug concentration range (50-300 µM) has lower anticancer activity compared with native VP-16, due to reduced intracellular transport of the more hydrophilic complex as indicated by the cell viability assay and confirmed by cell uptake study. However, at higher drug concentrations (500 µM) the complex's higher anticancer activity is ascribed to the synergistic effect between ARG and VP-16. These data suggest that an optimal ARG concentration can have positive effects with potential benefits for chemotherapy.


Assuntos
Arginina , Água , Arginina/química , Varredura Diferencial de Calorimetria , Composição de Medicamentos , Etoposídeo/farmacologia , Solubilidade , Água/química
3.
J Pharm Sci ; 110(11): 3605-3613, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34216578

RESUMO

Real time analysis of pharmaceuticals in controlled release nano and microsystems remains a challenge. It is hypothesized that fluorine 19 nuclear magnetic resonance (19F qNMR) can be used for real time quantification and in vitro release of maraviroc (MVC). The release of maraviroc was analyzed in simulated body fluids from spray dried sodium alginate microspheres (MS) using the 19F qNMR method. Calibration produced a linearity curve in concentration range (0.42 mg/ml - 15 mg/ml), and the limits of detection and quantification values were 0.97 mg/ml and 2.93 mg/ml, respectively. The method was confirmed to be specific, accurate, precise, and robust (%RSE > 2%). MVC was successfully microencapsulated (18% w/w) as evidenced by the FT-IR spectra and SEM images. The MS had an average diameter of 2.522 ± 0.15 µm, with a zeta potential of - 61.31 ± 2.1 mV. Overall, the 19F qNMR method enabled a direct and real time quantification of MVC for an efficient drug release kinetics. This approach could be potentially used to quantify fluorinated drug potency, purity, and stability, and evaluate in vitro release kinetic from different formulations.


Assuntos
Flúor , Liberação Controlada de Fármacos , Espectroscopia de Ressonância Magnética , Maraviroc , Espectroscopia de Infravermelho com Transformada de Fourier
4.
AAPS PharmSciTech ; 20(7): 254, 2019 Jul 17.
Artigo em Inglês | MEDLINE | ID: mdl-31317354

RESUMO

The pathophysiological mechanisms for dry and wet age-related macular degeneration (AMD) involve oxidative stress and increased VEGF release and expression. An ideal drug candidate for both types of AMD is the one which offers significant protection to the retinal cells from oxidative stress and inhibit VEGF release. Curcumin is one such natural product which provides numerous beneficial effects including antioxidant, anti-inflammatory, and anti-VEGF activities and has the potential for the treatment of both types of AMD. The bioavailability of curcumin is negligible due to its poor aqueous solubility. The purpose of this work is to develop an aqueous nanomicellar drop formulation of curcumin (CUR-NMF) for back of the eye delivery utilizing hydrogenated castor oil (HCO-40) and octoxynol-40 (OC-40) to treat AMD. A full factorial design was performed with JMP software analysis to optimize the formulation size, polydispersity index (PDI), entrapment efficiency, loading, and precipitation. MTT and LDH assays on human retinal pigmented epithelial (D407) cells revealed that 5-10 µM CUR-NMF dose is safe for ophthalmic use. Furthermore, CUR-NMF exhibited significant protection of retinal (D407) cells against H2O2-induced oxidative stress. In vitro drug release kinetics suggested a sustained drug release profile indicating a long-term protection ability of CUR-NMF against oxidative stress to retinal cells. In addition, an ELISA suggested that CUR-NMF significantly reduces vascular endothelial growth factor (VEGF) release in D407 cell line, hence diminishes the risk of angiogenesis. Collectively, these results suggest that the proposed CUR-NMF can be tremendously effective in treating both types of AMD.


Assuntos
Curcumina/administração & dosagem , Curcumina/farmacocinética , Olho/metabolismo , Micelas , Nanoestruturas , Administração Oftálmica , Antioxidantes/química , Disponibilidade Biológica , Óleo de Rícino/química , Linhagem Celular , Curcumina/farmacologia , Preparações de Ação Retardada , Humanos , Estresse Oxidativo/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Fator A de Crescimento do Endotélio Vascular/metabolismo
5.
Mol Pharm ; 16(2): 595-606, 2019 02 04.
Artigo em Inglês | MEDLINE | ID: mdl-30525661

RESUMO

Many novel vaginal/rectal microbicide formulations failed clinically due to safety concerns, indicating the need for the early investigation of lead microbicide formulations. In this study, the preclinical safety of an HIV-1 gp120 and mannose responsive microbicide delivery system (MRP) is evaluated in C57BL/6 mice. MRP was engineered through the layer-by-layer coating of calcium carbonate (CaCO3) with Canavalia ensiformis lectin (Con A) and glycogen. MRP mean particle diameter and zeta potential were 857.8 ± 93.1 nm and 2.37 ± 4.12 mV, respectively. Tenofovir (TFV) encapsulation and loading efficiencies in MRP were 70.1% and 16.3% w/w, respectively. When exposed to HIV-1 rgp120 (25 µg/mL), MRP released a significant amount of TFV (∼5-fold higher) in vaginal and seminal fluid mixture compared to the control (pre-exposure) level (∼59 µg/mL) in vaginal fluid alone. Unlike the positive control treated groups (e.g., nonoxynol-9), no significant histological damages and CD45+ cells infiltration were observed in the vaginal and major reproductive organ epithelial layers. This was probably due to MRP biocompatibility and its isosmolality (304.33 ± 0.58 mOsm/kg). Furthermore, compared to negative controls, there was no statistically significant increase in pro-inflammatory cytokines such as IL1α, Ilß, IL7, IP10, and TNFα. Collectively, these data suggest that MRP is a relatively safe nanotemplate for HIV-1 gp120 stimuli responsive vaginal microbicide delivery system.


Assuntos
Anti-Infecciosos/uso terapêutico , Proteína gp120 do Envelope de HIV/metabolismo , HIV-1/efeitos dos fármacos , HIV-1/patogenicidade , Administração Intravaginal , Animais , Carbonato de Cálcio/metabolismo , Quimiocinas/metabolismo , Difusão Dinâmica da Luz , Feminino , Infecções por HIV/tratamento farmacológico , Imuno-Histoquímica , Interleucina-1alfa/metabolismo , Interleucina-1beta/metabolismo , Interleucina-7/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Microscopia Eletrônica de Varredura , Concentração Osmolar , Tenofovir/uso terapêutico , Fator de Necrose Tumoral alfa/metabolismo , Vagina/virologia
6.
Mol Pharm ; 16(3): 967-977, 2019 03 04.
Artigo em Inglês | MEDLINE | ID: mdl-30525665

RESUMO

This study developed and validated a solution-state quantitative boron nuclear magnetic resonance (11B qNMR) method for the real-time quantification of boron containing bioactive agents with emerging therapeutic applications. Hence, this study may offer an alternative analytic method to estimate drug potency, purity, stability, or in vitro release kinetics of boron-containing pharmaceutical formulations/compounds, especially in cases where dialysis is typically required but limited. The 11B qNMR method was linear in the range tested, and the detection and quantification limits were 1.87 and 5.65 mM, respectively. The method was also specific, accurate, precise, and robust (%RSE < 2%). The 11B qNMR method was applied to the in vitro release study of a model drug, bortezomib (BTZ), from alginate microparticles, and results were compared to the traditional dialysis method. The alginate microparticles were prepared by spray drying, and the mean particle diameter was 2.36 ± 0.19 µm with a polydispersity index (PDI) of 0.253. The microparticles surface charge density was -57.1 ± 2.2 mV. More than 20% difference in the total amount of BTZ released from the microparticle formulation was observed between the direct 11B qNMR and dialysis methods. Furthermore, the dialysis method was not suitable to determine the initial burst release of BTZ from the microparticles. Throughout the release study, the dialysis method consistently underestimated the level of drug released, probably due to the separating membrane that can interfere with the real-time drug transport process. Overall, compared to the dialysis method, the direct 11B qNMR method was accurate and provided a direct and real-time quantification of BTZ for an effective study of drug release kinetics.


Assuntos
Alginatos/química , Boro , Bortezomib/química , Composição de Medicamentos/métodos , Liberação Controlada de Fármacos , Espectroscopia de Ressonância Magnética/métodos , Nanopartículas/química , Confiabilidade dos Dados , Diálise/métodos , Sistemas de Liberação de Medicamentos , Técnicas In Vitro , Isótopos/química , Limite de Detecção , Tamanho da Partícula , Solventes/química , Espectroscopia de Infravermelho com Transformada de Fourier
7.
Mol Pharm ; 14(10): 3512-3527, 2017 10 02.
Artigo em Inglês | MEDLINE | ID: mdl-28830144

RESUMO

The purpose of this study was to engineer a model anti-HIV microbicide (tenofovir) drug delivery system targeting HIV-1 envelope glycoprotein gp120 (HIV-1 g120) for the prevention of HIV sexual transmission. HIV-1 g120 and mannose responsive particles (MRP) were prepared through the layer-by-layer coating of calcium carbonate (CaCO3) with concanavalin A (Con A) and glycogen. MRP average particle size ranged from 881.7 ± 15.45 nm to 1130 ± 15.72 nm, depending on the number of Con A layers. Tenofovir encapsulation efficiency in CaCO3 was 74.4% with drug loading of 16.3% (w/w). MRP was non-cytotoxic to Lactobacillus crispatus, human vaginal keratinocytes (VK2), and murine macrophage RAW 264.7 cells and did not induce any significant proinflammatory nitric oxide release. Overall, compared to control, no statistically significant increase in proinflammatory cytokine IL-1α, IL-1ß, IL-6, MKC, IL-7, and interferon-γ-inducible protein 10 (IP10) levels was observed. Drug release profiles in the presence of methyl α-d-mannopyranoside and recombinant HIV-1 envelope glycoprotein gp120 followed Hixson-Crowell and Hopfenberg kinetic models, indicative of a surface-eroding system. The one Con A layer containing system was found to be the most sensitive (∼2-fold increase in drug release vs control SFS:VFS) at the lowest HIV gp120 concentration tested (25 µg/mL). Percent mucoadhesion, tested ex vivo on porcine vaginal tissue, ranged from 10% to 21%, depending on the number of Con A layers in the formulation. Collectively, these data suggested that the proposed HIV-1 g120 targeting, using MRP, potentially represent a safe and effective template for vaginal microbicide drug delivery, if future preclinical studies are conclusive.


Assuntos
Fármacos Anti-HIV/farmacologia , Anti-Infecciosos Locais/farmacologia , Engenharia Química/métodos , Sistemas de Liberação de Medicamentos/métodos , Proteína gp120 do Envelope de HIV/metabolismo , Infecções por HIV/prevenção & controle , HIV-1/efeitos dos fármacos , Administração Intravaginal , Animais , Bioensaio , Carbonato de Cálcio/química , Química Farmacêutica/métodos , Concanavalina A/química , Reagentes de Ligações Cruzadas/química , Liberação Controlada de Fármacos , Feminino , Glicogênio/química , Infecções por HIV/virologia , HIV-1/metabolismo , Humanos , Queratinócitos , Lactobacillus crispatus/efeitos dos fármacos , Metilmanosídeos/química , Camundongos , Nanopartículas/química , Células RAW 264.7 , Suínos , Tenofovir/farmacologia , Vagina/citologia , Vagina/microbiologia
8.
Biosens Bioelectron ; 59: 404-11, 2014 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-24768820

RESUMO

There is no comparative data available on the binding constants of Concanavalin A (Con A) and glycogen and Con A-mannan using quartz crystal microbalance (QCM), cost and time efficient system for biosensor analysis. It is hypothesized that a QCM can be used in its flow injection mode to monitor the binding affinity of polysaccharides to an immobilized lectin, Con A. The biosensor is prepared by immobilizing Con A on a 5MHz gold crystal by carbodiimide crosslinking chemistry. The attachment efficiency is monitored by Fourier Transform Infrared Spectroscopy. Equilibrium association and dissociation constants describing Con A-polysaccharides interaction are determined in a saturation binding experiment, where increasing concentrations of polysaccharides are run on a Con A-immobilized gold crystal surface, and the frequency shifts recorded on the frequency counter. The molecular weights (MW) of glycogen from Oyster and mannan from Saccharomyces cerevisiae are determined by size exclusion chromatography. The MW for glycogen and mannan are 604±0.002 kDa and 54±0.002 kDa, respectively. The equilibrium association and dissociation constants for Con A-glycogen and Con A-mannan interactions are KA=3.93±0.7×10(6) M(-1)/KD=0.25±0.06 µM and (n=3), respectively. Their respective frequency and motional resistance shifts relationship (ΔF/ΔR) are 37.29±1.55 and 34.86±0.85 Hz/Ω (n=3), which support the validity of Sauerbrey׳s rigidity approximation. This work suggests that Con A-mannan complex could be potentially utilized for insulin delivery and the targeting of glucose-rich substances and glycoproteins when fast drug release is desired.


Assuntos
Concanavalina A/metabolismo , Glicogênio/metabolismo , Ouro/química , Mananas/metabolismo , Técnicas de Microbalança de Cristal de Quartzo , Técnicas Biossensoriais , Canavalia/química , Concanavalina A/isolamento & purificação , Ligação Proteica , Técnicas de Microbalança de Cristal de Quartzo/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...